JP2000159749A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000159749A5 JP2000159749A5 JP2000008395A JP2000008395A JP2000159749A5 JP 2000159749 A5 JP2000159749 A5 JP 2000159749A5 JP 2000008395 A JP2000008395 A JP 2000008395A JP 2000008395 A JP2000008395 A JP 2000008395A JP 2000159749 A5 JP2000159749 A5 JP 2000159749A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- embedded image
- formula
- lower alkyl
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 84
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 9
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000004450 alkenylene group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000002944 cyanoaryl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 125000003106 haloaryl group Chemical group 0.000 claims description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 208000002249 Diabetes Complications Diseases 0.000 claims description 4
- 206010012655 Diabetic complications Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 2
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- 201000001421 hyperglycemia Diseases 0.000 claims description 2
- 230000008991 intestinal motility Effects 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 125000005948 methanesulfonyloxy group Chemical group 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010057469 Vascular stenosis Diseases 0.000 claims 1
- 150000008065 acid anhydrides Chemical class 0.000 claims 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 16
- 125000005843 halogen group Chemical group 0.000 description 11
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- -1 ester compound Chemical class 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 201000006641 Acquired generalized lipodystrophy Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 201000006705 Congenital generalized lipodystrophy Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000032780 Diabetic arthropathy Diseases 0.000 description 1
- 201000005948 Donohue syndrome Diseases 0.000 description 1
- 208000034669 Dunnigan type familial partial lipodystrophy Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000003929 Familial Partial Lipodystrophy Diseases 0.000 description 1
- 208000020970 Familial partial lipodystrophy, Dunnigan type Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010052004 Organic erectile dysfunction Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000016140 Rabson-Mendenhall syndrome Diseases 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7/343425 | 1995-12-28 | ||
| JP7-343425 | 1995-12-28 | ||
| JP34342595 | 1995-12-28 | ||
| JP8-287676 | 1996-10-08 | ||
| JP28767696 | 1996-10-08 | ||
| JP8/287676 | 1996-10-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9524201A Division JP3063162B2 (ja) | 1995-12-28 | 1996-12-27 | ベンズイミダゾール誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000159749A JP2000159749A (ja) | 2000-06-13 |
| JP2000159749A5 true JP2000159749A5 (enExample) | 2004-11-11 |
Family
ID=26556834
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9524201A Expired - Fee Related JP3063162B2 (ja) | 1995-12-28 | 1996-12-27 | ベンズイミダゾール誘導体 |
| JP2000008395A Pending JP2000159749A (ja) | 1995-12-28 | 2000-01-17 | ベンズイミダゾ―ル誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9524201A Expired - Fee Related JP3063162B2 (ja) | 1995-12-28 | 1996-12-27 | ベンズイミダゾール誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6166219A (enExample) |
| EP (1) | EP0882718B1 (enExample) |
| JP (2) | JP3063162B2 (enExample) |
| CN (1) | CN1211238A (enExample) |
| AT (1) | ATE303365T1 (enExample) |
| AU (1) | AU722514B2 (enExample) |
| BR (1) | BR9612434A (enExample) |
| DE (1) | DE69635135T2 (enExample) |
| DK (1) | DK0882718T3 (enExample) |
| EA (1) | EA002357B1 (enExample) |
| ES (1) | ES2244979T3 (enExample) |
| HU (1) | HUP9900625A3 (enExample) |
| IL (1) | IL124969A (enExample) |
| NZ (1) | NZ324834A (enExample) |
| TR (1) | TR199801249T2 (enExample) |
| WO (1) | WO1997024334A1 (enExample) |
Families Citing this family (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997048697A1 (en) | 1996-06-19 | 1997-12-24 | Rhone-Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| TW453999B (en) * | 1997-06-27 | 2001-09-11 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| DE69826286T2 (de) | 1997-06-27 | 2005-11-24 | Fujisawa Pharmaceutical Co., Ltd. | Derivate mit einem aromatischen ring |
| EP0995742A4 (en) * | 1997-06-27 | 2004-08-25 | Fujisawa Pharmaceutical Co | SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE |
| ES2222613T3 (es) * | 1997-09-12 | 2005-02-01 | Pharis Biotec Gmbh | Composicion para la terapia de diabetes mellitus y de la obesidad. |
| US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
| BR9909440A (pt) * | 1998-04-06 | 2000-12-26 | Fujisawa Pharmaceutical Co | Derivados de indol |
| US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
| EP1132087A4 (en) * | 1998-11-13 | 2002-06-26 | Fujisawa Pharmaceutical Co | REMEDIES FOR POLYKYSTIC OVARY SYNDROME |
| US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
| US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
| US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
| US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
| US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
| US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
| WO2000034277A1 (en) | 1998-12-04 | 2000-06-15 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonamide compounds and uses thereof as medicines |
| ES2292262T3 (es) | 1998-12-24 | 2008-03-01 | Astellas Pharma Inc. | Compuestos de imidazol y su uso medicinal. |
| EP1142880A4 (en) | 1998-12-24 | 2002-02-27 | Fujisawa Pharmaceutical Co | BENZIMIDAZOLE DERIVATIVES |
| US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
| US6627624B1 (en) | 1999-04-02 | 2003-09-30 | Neurogen Corporation | Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6358949B1 (en) | 1999-04-02 | 2002-03-19 | Neurogen Corporation | Aryl and hetroaryl fused aminoalkyl-imidazole derivatives: selective modulators of bradykinin B2 receptors |
| US6281237B1 (en) | 1999-04-02 | 2001-08-28 | Neurogen Corporation | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives |
| AU4055400A (en) * | 1999-04-02 | 2000-10-23 | Neurogen Corporation | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| US6271241B1 (en) | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
| US6380210B1 (en) | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| FR2792635B1 (fr) * | 1999-04-20 | 2001-06-01 | Synthelabo | Derives de cyclobutene-3,4-dione leur preparation et leur application en therapeutique |
| JP2001169268A (ja) * | 1999-12-14 | 2001-06-22 | Sony Corp | 情報提供システム、送信サーバ、情報端末装置、オーサリング装置及び情報提供方法 |
| GB9914255D0 (en) * | 1999-06-18 | 1999-08-18 | Lilly Forschung Gmbh | Pharmaceutical compounds |
| KR20020020788A (ko) | 1999-07-21 | 2002-03-15 | 후지야마 아키라 | 벤즈이미다졸론 유도체 및 포스포디에스테라제억제제로서의 이의 용도 |
| IL152925A (en) * | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
| US6770666B2 (en) * | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| NZ514403A (en) | 1999-12-27 | 2002-10-25 | Japan Tobacco Inc | Fused-ring compounds and use thereof as drugs |
| GB0000561D0 (en) * | 2000-01-11 | 2000-03-01 | Pfizer Ltd | Treatment of diabetic ulcers |
| JP2004500425A (ja) * | 2000-04-19 | 2004-01-08 | リリー アイコス リミテッド ライアビリティ カンパニー | パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用 |
| KR20030023747A (ko) * | 2000-08-11 | 2003-03-19 | 화이자 인코포레이티드 | 인슐린 저항성 증후군의 치료 |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| DE10060292A1 (de) | 2000-12-05 | 2002-06-20 | Aventis Pharma Gmbh | Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament |
| WO2002046168A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
| US7022728B2 (en) | 2001-03-09 | 2006-04-04 | Abbott Laboratories | Benzimidazoles that are useful in treating male sexual dysfunction |
| US20020169166A1 (en) * | 2001-03-09 | 2002-11-14 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| US6960589B2 (en) | 2001-03-09 | 2005-11-01 | Abbott Laboratories | Benzimidazoles that are useful in treating sexual dysfunction |
| KR100863147B1 (ko) * | 2001-03-09 | 2008-10-13 | 아보트 러보러터리즈 | 벤즈이미다졸 및 이를 포함하는 성 기능장애 치료용 약제학적 조성물 |
| JP2002363169A (ja) * | 2001-06-08 | 2002-12-18 | Fujiyakuhin Co Ltd | 抗腫瘍活性を有する複素環化合物 |
| AR035543A1 (es) * | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| WO2003037432A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| WO2003042216A1 (en) | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
| WO2003047573A1 (en) * | 2001-12-03 | 2003-06-12 | Takeda Chemical Industries, Ltd. | Insulin resistance improving agents |
| KR100614862B1 (ko) * | 2001-12-28 | 2006-08-22 | 다케다 야쿠힌 고교 가부시키가이샤 | 배뇨 장애 예방제/치료제 |
| US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US7279576B2 (en) * | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US20050048573A1 (en) * | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
| SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| AU2003902860A0 (en) * | 2003-06-06 | 2003-06-26 | Daicel Chemical Industries, Ltd | Benzimidazole compounds |
| SE0301698D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0301701D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| SE0301699D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| JP2007521296A (ja) * | 2003-07-01 | 2007-08-02 | メルク エンド カムパニー インコーポレーテッド | 高眼圧の治療のための眼科用組成物 |
| TW200517381A (en) * | 2003-08-01 | 2005-06-01 | Genelabs Tech Inc | Bicyclic heteroaryl derivatives |
| AU2003266526A1 (en) * | 2003-09-17 | 2005-04-11 | Kaname Kawasugi | Medicinal composition |
| SE0302573D0 (sv) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| JP4355917B2 (ja) * | 2003-10-29 | 2009-11-04 | 信越化学工業株式会社 | 含窒素有機化合物、レジスト材料及びパターン形成方法 |
| WO2005082414A2 (en) * | 2004-03-02 | 2005-09-09 | Astellas Pharma Inc. | Concomitant drugs of a sulfonamide and another therapeutic agent |
| CA2560928A1 (en) * | 2004-03-29 | 2005-10-06 | Sankyo Company Limited | Therapeutic agent for diabetes containing insulin resistance improving agent |
| US7915443B2 (en) * | 2006-11-16 | 2011-03-29 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| TW200608967A (en) * | 2004-07-29 | 2006-03-16 | Sankyo Co | Pharmaceutical compositions containing with diabetic agent |
| KR101269869B1 (ko) * | 2004-09-24 | 2013-06-07 | 네오메드 인스티튜트 | 벤즈이미다졸 유도체, 그를 함유하는 조성물, 그의 제조방법 및 그의 용도 |
| CN101133036B (zh) * | 2004-09-30 | 2010-10-13 | 詹森药业有限公司 | 可用作选择性雄激素受体调节剂(sarms)的新苯并咪唑衍生物 |
| RU2403240C2 (ru) * | 2004-10-12 | 2010-11-10 | Декод Дженетикс Ехф | Сульфонамидные пери-замещенные бициклы для лечения окклюзионного поражения артерий |
| NZ554492A (en) * | 2004-10-12 | 2010-07-30 | Decode Genetics Ehf | Carboxylic acid peri-substituted bicyclics for occlusive artery disease |
| RU2394027C2 (ru) * | 2004-10-27 | 2010-07-10 | Ф. Хоффманн-Ля Рош Аг | Новые индольные или бензимидазольные производные |
| ES2318556T3 (es) * | 2004-11-02 | 2009-05-01 | Pfizer, Inc. | Derivados de sulfonil bencimidazol. |
| EP1676573A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor |
| RU2007130896A (ru) * | 2005-01-14 | 2009-02-20 | Дженелэбс Текнолоджиз, Инк. (Us) | Индольные производные для лечения вирусных инфекций |
| KR20080028415A (ko) * | 2005-07-12 | 2008-03-31 | 다이이찌 산쿄 가부시키가이샤 | ＰＰＡＲγ 애고니스트를 함유하는 의약 조성물 |
| GB0515025D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| EP2308852A1 (de) | 2005-08-21 | 2011-04-13 | Abbott GmbH & Co. KG | 5-Ring-Heteroaromaten-Verbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
| TW200804345A (en) | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
| ES2246742B1 (es) * | 2005-09-06 | 2007-02-01 | Prous Institute For Biomedical Research S.A. | Uso de un derivado de imidazol. |
| TW200736227A (en) | 2005-12-23 | 2007-10-01 | Astrazeneca Ab | New compounds III |
| ATE550329T1 (de) * | 2006-02-13 | 2012-04-15 | Hoffmann La Roche | Heterobicyclische sulfonamidderivate zur behandlung von diabetes |
| DE602007009807D1 (de) * | 2006-03-06 | 2010-11-25 | Raqualia Pharma Inc | Sulfonylbenzimidazolderivate |
| TW200745049A (en) | 2006-03-23 | 2007-12-16 | Astrazeneca Ab | New crystalline forms |
| TW200808769A (en) * | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
| CN101490045A (zh) | 2006-05-16 | 2009-07-22 | 解码遗传Ehf公司 | 7-(丙烯酰基)吲哚的制备方法 |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| PE20080888A1 (es) * | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
| AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| US8501957B2 (en) * | 2008-12-10 | 2013-08-06 | China Medical University | Benzimidazole compounds and their use as anticancer agents |
| WO2010127246A2 (en) * | 2009-04-30 | 2010-11-04 | Burnham Institute For Medical Research | Hnf4 modulators and methods of use |
| WO2011014600A1 (en) | 2009-07-30 | 2011-02-03 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with benzimidazole derivative agonists of ppargamma |
| US20110086853A1 (en) * | 2009-10-08 | 2011-04-14 | William Brown | Therapeutic Compounds |
| TWI458714B (zh) * | 2009-12-10 | 2014-11-01 | Univ China Medical | 苯并咪唑化合物及其用途 |
| RU2414899C1 (ru) * | 2009-12-29 | 2011-03-27 | Аверин Константин Михайлович | Средства для лечения рассеянного склероза |
| EP2397471A1 (en) * | 2010-06-16 | 2011-12-21 | China Medical University | Benzimidazole compounds and their use |
| JP5782234B2 (ja) * | 2010-06-16 | 2015-09-24 | チャイナ メディカル ユニヴァーシティーＣｈｉｎａ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ | ベンゾイミダゾール化合物およびその使用 |
| AU2011326071A1 (en) * | 2010-11-08 | 2013-05-23 | Lycera Corporation | N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases |
| US8987473B2 (en) | 2011-01-28 | 2015-03-24 | Sato Pharmaceutical Co., Ltd. | Ring-fused compound |
| WO2012174312A2 (en) * | 2011-06-15 | 2012-12-20 | Glaxosmithkline Llc | Benzimidazole derivatives as antiviral agents |
| MX367341B (es) | 2012-05-08 | 2019-08-14 | Merck Sharp & Dohme | Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades. |
| US9394315B2 (en) | 2012-05-08 | 2016-07-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| CN102702006A (zh) * | 2012-05-24 | 2012-10-03 | 盛世泰科生物医药技术(苏州)有限公司 | 一种3-氨基-2-硝基苯甲酸乙酯的制备方法 |
| TR201807207T4 (tr) * | 2012-06-11 | 2018-06-21 | Ucb Biopharma Sprl | Tnf-alfa modüle edici benzimidazol bileşikleri. |
| US9512119B2 (en) | 2012-07-27 | 2016-12-06 | Sato Pharmaceutical Co., Ltd. | Difluoromethylene compound |
| CN102827084A (zh) * | 2012-08-21 | 2012-12-19 | 江苏恒祥化工有限责任公司 | 一种2-(二氯甲基)苯并咪唑的制备方法 |
| WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
| WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| EA031804B1 (ru) | 2014-02-03 | 2019-02-28 | Вайтаи Фармасьютиклз, Инк. | Дигидропирролопиридиновые ингибиторы ror-гамма |
| CA2939305A1 (en) | 2014-02-27 | 2015-09-03 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
| WO2015171558A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE |
| CA2947290A1 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| JP6687550B2 (ja) | 2014-06-23 | 2020-04-22 | セルジーン コーポレイション | 肝疾患又は肝機能異常を治療するためのアプレミラスト |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| CN104860919B (zh) * | 2015-03-26 | 2017-11-10 | 天津药物研究院有限公司 | 含哌啶的苯并咪唑衍生物及其制备方法和用途 |
| JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 |
| EP3307738B1 (en) | 2015-06-11 | 2022-04-20 | The Regents of the University of Michigan | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| CA3002846A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as rorgammat inhibitors and uses thereof |
| WO2017075182A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
| WO2017075185A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| CN108463458B (zh) | 2015-11-20 | 2022-02-01 | 生命医药有限责任公司 | ROR-γ的调节剂 |
| JP6456520B2 (ja) | 2015-12-11 | 2019-01-23 | 帝人ファーマ株式会社 | アミノアゾール誘導体 |
| TW202220968A (zh) * | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| CN108689942B (zh) * | 2017-04-11 | 2023-06-09 | 广东东阳光药业有限公司 | 含氮双环化合物及其制备方法和用途 |
| CN107311933B (zh) * | 2017-06-28 | 2020-12-22 | 中国人民解放军军事医学科学院毒物药物研究所 | 一类苯并咪唑衍生物，及其制备方法和用途 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| WO2019023207A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of rorϒ |
| CN108947911B (zh) * | 2018-07-03 | 2022-02-22 | 中山大学 | 一种具有抗乙肝病毒活性和抗菌活性的苯并咪唑类化合物及其合成方法和应用 |
| CN111116485B (zh) * | 2019-12-24 | 2022-11-11 | 山西大学 | 一种5,6-双（4-氨基苄基）-2-三氟甲基-1h-苯并咪唑的制备方法 |
| CN111057011B (zh) * | 2019-12-24 | 2022-11-11 | 山西大学 | 一种5,6-双（4-氨基苄基）-1-甲基-2-苯基苯并咪唑的制备方法 |
| CN111116484B (zh) * | 2019-12-24 | 2022-11-11 | 山西大学 | 一种5,6-双（4-氨基苄基）-1,2二甲基-苯并咪唑的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE676196C (de) * | 1936-08-21 | 1939-05-30 | I G Farbenindustrie Akt Ges | Verfahren zur Herstellung von Imidazolverbindungen |
| US3152142A (en) * | 1962-05-24 | 1964-10-06 | Dow Chemical Co | Benzimidazole compounds |
| US4243813A (en) | 1974-07-01 | 1981-01-06 | Eli Lilly And Company | Substituted 1-sulfonylbenzimidazoles |
| FR2291749A1 (fr) * | 1974-11-20 | 1976-06-18 | Delalande Sa | Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique |
| JPS51133267A (en) * | 1975-05-08 | 1976-11-18 | Lilly Co Eli | Substituted 11sulphonyl benzimidazole |
| US4179505A (en) * | 1977-03-30 | 1979-12-18 | Janssen Pharmaceutica N.V. | 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives |
| US4243806A (en) * | 1979-06-13 | 1981-01-06 | Janssen Pharmaceutica N.V. | 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives |
| GB2053215B (en) * | 1979-06-25 | 1983-04-07 | May & Baker Ltd | Benzimidazole derivatives |
| JPS625966A (ja) * | 1985-07-03 | 1987-01-12 | Nippon Shinyaku Co Ltd | ベンズイミダゾ−ル誘導体 |
| NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
| CA2004911A1 (en) * | 1988-12-22 | 1990-06-22 | Mitsuaki Ohta | 4,5,6,7-tetrahydrobenzimidazole derivatives |
| JPH03218362A (ja) * | 1988-12-22 | 1991-09-25 | Yamanouchi Pharmaceut Co Ltd | ４，５，６，７―テトラヒドロベンズイミダゾール誘導体及びそれを含有する医薬 |
| AU7759591A (en) * | 1990-04-13 | 1991-11-11 | Smithkline Beecham Corporation | Substituted benzimidazoles |
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5703110A (en) * | 1990-04-27 | 1997-12-30 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives, their production and use |
| RU1836357C (ru) * | 1990-07-23 | 1993-08-23 | Др.Карл Томэ ГмбХ | Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами |
| DE4224133A1 (de) * | 1992-07-22 | 1994-01-27 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5594003A (en) * | 1991-02-06 | 1997-01-14 | Dr. Karl Thomae Gmbh | Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists |
| US5602127A (en) * | 1991-02-06 | 1997-02-11 | Karl Thomae Gmbh | (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists |
| US5614519A (en) * | 1991-02-06 | 1997-03-25 | Karl Thomae Gmbh | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists |
| GB9121776D0 (en) * | 1991-10-14 | 1991-11-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives and process for preparation thereof |
| DE4237557A1 (de) * | 1992-11-06 | 1994-05-11 | Bayer Ag | Substituierte Benzimidazole |
| JPH0853424A (ja) * | 1994-08-11 | 1996-02-27 | Kureha Chem Ind Co Ltd | ベンズイミダゾールスルホン酸アミド誘導体 |
| GB9423910D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| JPH11154208A (ja) | 1997-11-21 | 1999-06-08 | Mitsubishi Electric Corp | Ｉｃカード及びその製造方法 |
-
1996
- 1996-12-27 WO PCT/JP1996/003858 patent/WO1997024334A1/ja not_active Ceased
- 1996-12-27 EA EA199800609A patent/EA002357B1/ru not_active IP Right Cessation
- 1996-12-27 ES ES96943331T patent/ES2244979T3/es not_active Expired - Lifetime
- 1996-12-27 HU HU9900625A patent/HUP9900625A3/hu unknown
- 1996-12-27 BR BR9612434-2A patent/BR9612434A/pt not_active Application Discontinuation
- 1996-12-27 NZ NZ324834A patent/NZ324834A/en unknown
- 1996-12-27 US US09/091,997 patent/US6166219A/en not_active Expired - Lifetime
- 1996-12-27 TR TR1998/01249T patent/TR199801249T2/xx unknown
- 1996-12-27 JP JP9524201A patent/JP3063162B2/ja not_active Expired - Fee Related
- 1996-12-27 IL IL12496996A patent/IL124969A/en not_active IP Right Cessation
- 1996-12-27 AT AT96943331T patent/ATE303365T1/de not_active IP Right Cessation
- 1996-12-27 AU AU12095/97A patent/AU722514B2/en not_active Ceased
- 1996-12-27 DK DK96943331T patent/DK0882718T3/da active
- 1996-12-27 DE DE69635135T patent/DE69635135T2/de not_active Expired - Lifetime
- 1996-12-27 EP EP96943331A patent/EP0882718B1/en not_active Expired - Lifetime
- 1996-12-27 CN CN96180137A patent/CN1211238A/zh active Pending
-
2000
- 2000-01-17 JP JP2000008395A patent/JP2000159749A/ja active Pending
- 2000-01-28 US US09/492,955 patent/US6352985B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000159749A5 (enExample) | ||
| JP2815617B2 (ja) | 縮合ピリミジン誘導体およびその製造方法 | |
| EP1372656B1 (en) | Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors | |
| CN1247583C (zh) | 三唑并[4,5－d]嘧啶化合物的新晶形和非晶形 | |
| CN1187367C (zh) | 具有麻醉剂活性的3α－羟基－3β－甲氧基甲基－21－杂环取代的类固醇 | |
| FI88504B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-benzyl-1-(2h)-ftalazinonderivat | |
| CN1346349A (zh) | 吡唑甲酸类衍生物、其制备方法和含有它们的药物组合物 | |
| US9452169B2 (en) | Substituted diketopiperazines and their use as oxytocin antagonists | |
| SK4562002A3 (en) | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors | |
| CN1671377A (zh) | 作为大麻素－cb1受体配体的1h－1,2,4－三唑－3－酰胺衍生物 | |
| CN1333767A (zh) | 作为消炎剂的芳香族杂环化合物 | |
| WO2000012487A1 (en) | Pyrimidine derivatives | |
| CN110997653B (zh) | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 | |
| CN1913885A (zh) | 具有cb1－拮抗活性的1,3,5－三取代的4,5－二氢－1h－吡唑衍生物 | |
| CN1065460A (zh) | 衍生于苯并咪唑的新的非镇静抗组胺剂 | |
| CN105051031B (zh) | 1‑([1,3]二氧戊环‑4‑基甲基)‑1h‑吡唑‑3‑胺的制备方法 | |
| JP2002526410A5 (enExample) | ||
| JPWO2016204153A1 (ja) | 置換ジヒドロピロロピラゾール誘導体 | |
| CN1711261A (zh) | 咪唑并吡啶衍生物、它们的制备方法以及含有它们的药物组合物 | |
| JP3204456B2 (ja) | ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体 | |
| JPH0417190B2 (enExample) | ||
| ZA200307507B (en) | Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors. | |
| WO1993013739A2 (en) | Retroreverse pyrrole-amidino oligopeptide anticancer agent analogues, preparation of same, and pharmaceutical compositions containing such analogues | |
| MX2007009234A (es) | Dicetoacidos con estructuras nucleo-base: inhibidores anti-replicacion del vih por inhibicion de la integrasa del vih. | |
| JPH11506425A (ja) | エチニルチアゾール誘導体 |